Advances in Breast Cancer Treatment: New Findings from Belgium, Ireland, and the United States

Strategic Insights -

Recent studies from Belgium, Ireland, and the United States have made significant strides in breast cancer treatment, shedding light on the cost-effectiveness of Herceptin, a humanized monoclonal antibody, and the accuracy of Her2 protein expression measurement in breast carcinoma. Researchers have also explored the potential of combining lapatinib, a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies to enhance apoptosis of ErbB2-overexpressing breast cancer cells.

Key Takeaways:

  • A study from Belgium provides essential information for price-setting policies and reimbursement of Herceptin in breast cancer therapy, estimating treatment costs and cost-effectiveness ratios.
  • Researchers from Ireland compared immunohistochemistry (IHC) using CBE356 antibody with IHC using the Food and Drug Administration-approved HercepTest, finding that CBE356 is a more accurate predictor of Her2 gene amplification by fluorescence in situ hybridization (FISH) in breast carcinoma.
  • Scientists in the United States discovered that combining lapatinib with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells, providing a potential therapeutic strategy to improve clinical response.

Statistics:

  • The study from Belgium estimated treatment costs of EUR 45,034 and EUR 47,765 for trastuzumab-based treatments, with 79% and 75% of the costs attributed to trastuzumab, respectively.
  • The sensitivity, specificity, predictive values, and overall accuracy of CBE356 in predicting Her2 gene amplification by FISH were 94%, 89%, 84%, and 97%, respectively.
  • The combination of lapatinib and anti-ErbB2 antibodies led to a significant increase in apoptosis, demonstrating a 3% greater accuracy and 23% greater sensitivity in predicting Her2 gene amplification compared to HercepTest.

Sources:

  • Neyt, M., et al. (2006) "An economic evaluation of Herceptin in adjuvant setting: The Breast Cancer International Research Group 006 trial." Annals of Oncology, 17(3), 381-390.
  • Ainsworth, R., et al. (2005) "IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma." Journal of Clinical Pathology, 58(10), 1086-1090.
  • Xia, W., et al. (2005) "Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells." Oncogene, 24(41), 6213-6221.